These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 26027044)

  • 1. Vaginal atrophy. Treatment options.
    Mayo Clin Health Lett; 2014 Nov; 32(11):7. PubMed ID: 26027044
    [No Abstract]   [Full Text] [Related]  

  • 2. A case for prophylactic vaginal estrogen?
    Morris E; Currie H
    Menopause Int; 2010 Dec; 16(4):135. PubMed ID: 21156848
    [No Abstract]   [Full Text] [Related]  

  • 3. Vaginal atrophy in breast cancer survivors: role of vaginal estrogen therapy.
    Mariani L; Gadducci A; Vizza E; Tomao S; Vici P
    Gynecol Endocrinol; 2013 Jan; 29(1):25-9. PubMed ID: 22994445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. By the way, doctor. My doctor prescribed a low-dose vaginal estrogen cream, applied twice a week, for atrophic vaginitis. I've heard this dose is so low that it carries no health risk. Do you agree?
    Robb-Nicholson C
    Harv Womens Health Watch; 2007 Nov; 15(3):7. PubMed ID: 18225330
    [No Abstract]   [Full Text] [Related]  

  • 5. A multicentre Australian trial of low dose estradiol therapy for symptoms of vaginal atrophy using a vaginal ring as delivery system.
    Fraser IS; Ayton R; Farrell E; Weisberg E; Darling G; Murkies A
    Maturitas; 1995 Dec; 22 Suppl():S41. PubMed ID: 8775776
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaginal estrogen preparations for relief of atrophic vaginitis.
    Nothnagle M; Taylor JS
    Am Fam Physician; 2004 May; 69(9):2111-2. PubMed ID: 15152956
    [No Abstract]   [Full Text] [Related]  

  • 7. Vulvovaginal atrophy: new and upcoming approaches.
    Simon JA
    Menopause; 2009; 16(1):5-7. PubMed ID: 19131842
    [No Abstract]   [Full Text] [Related]  

  • 8. Topical estrogen therapy in the management of postmenopausal vaginal atrophy: an up-to-date overview.
    Al-Baghdadi O; Ewies AA
    Climacteric; 2009 Apr; 12(2):91-105. PubMed ID: 19117185
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravaginal oestrogen and progestin administration: advantages and disadvantages.
    Cicinelli E
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):391-405. PubMed ID: 17981510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Management of vulvovaginal atrophy-related sexual dysfunction in postmenopausal women: an up-to-date review.
    Tan O; Bradshaw K; Carr BR
    Menopause; 2012 Jan; 19(1):109-17. PubMed ID: 22011753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal DHEA to treat menopause related atrophy: a review of the evidence.
    Panjari M; Davis SR
    Maturitas; 2011 Sep; 70(1):22-5. PubMed ID: 21733647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of The North American Menopause Society.
    North American Menopause Society
    Menopause; 2007; 14(3 Pt 1):355-69; quiz 370-1. PubMed ID: 17438512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy.
    Rees M; Pérez-López FR; Ceasu I; Depypere H; Erel T; Lambrinoudaki I; Schenck-Gustafsson K; Simoncini T; van der Schouw Y; Tremollieres F;
    Maturitas; 2012 Oct; 73(2):171-4. PubMed ID: 22818886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Why the product labeling for low-dose vaginal estrogen should be changed.
    Manson JE; Goldstein SR; Kagan R; Kaunitz AM; Liu JH; Pinkerton JV; Rebar RW; Schnatz PF; Shifren JL; Stuenkel CA; Gass ML; Utian WH;
    Menopause; 2014 Sep; 21(9):911-6. PubMed ID: 25140698
    [No Abstract]   [Full Text] [Related]  

  • 15. A randomized, placebo- and active-controlled trial of bazedoxifene/conjugated estrogens for treatment of moderate to severe vulvar/vaginal atrophy in postmenopausal women.
    Kagan R; Williams RS; Pan K; Mirkin S; Pickar JH
    Menopause; 2010 Mar; 17(2):281-9. PubMed ID: 19779382
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Newer Name, Newer Treatments: The Genitourinary Syndrome of Menopause.
    Vegunta S; Files J; Kling JM
    J Womens Health (Larchmt); 2019 Jul; 28(7):897-899. PubMed ID: 31334693
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of bazedoxifene/conjugated estrogens on quality of life in postmenopausal women with symptoms of vulvar/vaginal atrophy.
    Bachmann G; Bobula J; Mirkin S
    Climacteric; 2010 Apr; 13(2):132-40. PubMed ID: 19863455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drugs for menopausal symptoms.
    Med Lett Drugs Ther; 2016 Nov; 58(1507):142-145. PubMed ID: 27805574
    [No Abstract]   [Full Text] [Related]  

  • 19. The first published randomised controlled trial of laser treatment for vaginal atrophy raises serious questions.
    Buttini MJ; Maher C
    Med J Aust; 2018 Nov; 209(9):376-377. PubMed ID: 30376654
    [No Abstract]   [Full Text] [Related]  

  • 20. Conjugated estrogens (Premarin) vaginal cream.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):14-5. PubMed ID: 19229162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.